Shots: The P-III IMMhance study results involves assessing of Skyrizi (SC, 150mg) vs PBO in patients in a ratio (4:1) for moderate to severe plaque psoriasis for 2yrs. The P-III IMMhance study results: @94wk. complete skin clearance; sPGA 0 (73%); PASI 100 (72%); @16wks. met 1EPs of the first phase of the study; @52wks. met […]Read More
Shots: The EC approval is based on four P-III ultIMMa-1, ultIMMa-2, IMMvent & IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in 2000+ adult patients with moderate to severe plaque psoriasis The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); switched patients […]Read More
Shots: The Health Canada approval is based on four P-III studies ultIMMa-1, ultIMMa-2, IMMvent and IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in >2000 adult patients with moderate to severe plaque psoriasis The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); […]Read More
Shots: The approval is based on P-II & P-III sustaIMM, ultIMMa-1 and IMMspire study results assessing Skyrizi in Japanese patients with plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis & active psoriatic arthritis The study resulted in safe and effective results and has capabilities to improve the signs of these chronic immune-mediated diseases Skyrizi (risankizumab) […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
